Global Congress on Women’s Health, Hormones & Reproductive Medicine
Global Congress on Women’s Health, Hormones & Reproductive Medicine
The Global Congress on Women’s Health, Hormones & Reproductive Medicine 2026 will take place on 22–23 June 2026 in Lisbon. This international event is dedicated to advancing science, care, and equity across every stage of a woman’s life—from adolescence to menopause and beyond.
The congress brings together clinicians, endocrinologists, gynecologists, reproductive medicine specialists, researchers, and public health leaders to share discoveries and strategies in hormonal health, fertility, pregnancy care, gynecology, cancer, and mental well-being.
Key Features:
-
Keynote Speakers: Leading experts in endocrinology, gynecology, and reproductive medicine.
-
Oral & Poster Presentations: Covering PCOS, menopause, maternal health, and more.
-
Panel Discussions: Hormone therapy, fertility preservation, global health equity, and femtech.
-
Workshops & Training: Hands-on learning in fertility assessment, menopause care, and adolescent health.
-
Exhibitions & Innovation Showcase: Latest reproductive technologies, diagnostics, telehealth, and wellness tools.
-
Women’s Health Excellence Awards: Recognising best oral/poster presentations, rising researchers, and innovations.
Scientific Sessions Include:
-
Endocrinology of Women: hormones across the lifespan
-
Reproductive endocrinology & infertility
-
Maternal-fetal medicine & pregnancy care
-
Gynecological disorders, surgery & pelvic health
-
Women’s cancers: prevention & treatment
-
Midlife & menopause: healthy aging
-
Mental health, stress & psychoneuroendocrinology
-
Global health equity & innovation in women’s health
Target Audience:
-
Gynecologists, obstetricians & fertility specialists
-
Endocrinologists & hormone researchers
-
Maternal-fetal medicine experts, nurses & midwives
-
Oncologists, psychologists & public health leaders
-
Biomedical scientists & researchers
-
Pharma, MedTech & FemTech professionals
-
Patient advocates and health educators
Organizer: Scirator Conferences
Contact: +1 302-231-1414 | info@sciratorconferences.com
FT World does not take responsibility for any changes to this event, which we have published in good faith. Please direct any queries to the organiser.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks ago
Parents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks ago
Women’s health could unlock US$100bn by 2030
-
Insight4 weeks ago
China’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks ago
HRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days ago
US startup builds wearable hormone tracker
-
Menopause3 weeks ago
Flo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks ago
Study reveals gap between perimenopause expectations and experience
-
Fertility6 days ago
France urges 29-year-olds to start families now






